Reasons to Retain Penumbra Stock in Your Portfolio for Now

Penumbra, Inc.’s (PEN) thrombectomy business is thriving, driven by growing sales of the U.S. vascular thrombectomy and CAVT (computer-assisted vacuum thrombectomy) line of products. The company’s robust product portfolio expansion is poised to drive growth in the upcoming quarters. Meanwhile, unfavorable foreign exchange and intense competition may pose operational risks for PEN.               In the past year, shares of this Zacks Rank #2 (Buy) company have increased 19.8% against the industry’s 18.4% dec ...